CTX-10726 for Cancer

Recruiting at 3 trial locations

Overseen By Talia Fountain

Age: 18+

Sex: Any

Trial Phase: Phase 1

Sponsor: Compass Therapeutics

Must be taking: PD-1/PDL1, Tyrosine kinase inhibitors

Must not be taking: Anticoagulants, NSAIDs

Disqualifiers: Organ transplantation, CNS metastasis, others

No Placebo Group All trial participants will receive the active study treatment (no placebo)

Compensation: Varies

Number of Visits: 4

70 Participants Needed

What You Need to Know Before You Apply

What is the purpose of this trial?

This is a Phase 1, open-label, first-in-human study of CTX-10726 monotherapy in patients with metastatic or locally advanced malignancies. The study will be conducted in 2 Cohorts: Cohort 1 Dose Escalation and Cohort 2 Dose Expansion.

Who Is on the Research Team?

Cynthia Sirard, MD

Principal Investigator

Compass Therapeutics

Are You a Good Fit for This Trial?

Inclusion Criteria

I have not taken immune-boosting drugs in the past 2 weeks or had major surgery in 3 weeks.

I have been diagnosed with hepatocellular carcinoma (HCC).

I have had at least 2 doses of PD-1/PD-L1 treatment and my cancer has worsened.

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Dose Escalation

Participants receive escalating doses of CTX-10726 to evaluate safety and tolerability

6 months

IV infusion once every 2 weeks

Dose Expansion

Participants receive CTX-10726 at doses determined from the Dose Escalation phase

up to 2 years

IV infusion once every 2 weeks

Follow-up

Participants are monitored for safety and effectiveness after treatment

4 weeks

What Are the Treatments Tested in This Trial?

Interventions

• CTX-10726

How Is the Trial Designed?

Group I: Dose Expansion Cohort 2 Experimental Treatment 1 Intervention

Dose of CTX-10726 depending on Cohort 1 data

Group II: Dose Escalation Cohort 1 Experimental Treatment 1 Intervention

Escalating doses of CTX-10726

Who Is Running the Clinical Trial?

Compass Therapeutics

Lead Sponsor

Trials

5

Recruited

430+